Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade.

Background

Despite impressive advancements in cancer therapy due to novel treatment approaches such as immune checkpoint blockade (ICB), cancer patients still experience relapse, severe side effects, and poor quality of life. Established therapies frequently fail to induce sufficient and sustainable tumor regression. However, novel adjuvant therapies, immunotherapy, and extensive monitoring of the anti-tumor immune response are helping to mitigate these hallmarks of cancer.

A major challenge is that cancer cells often induce an immune-suppressive tumor microenvironment (TME) which impedes the body’s anti-tumor immunity [ 1 ]. These so-called immunologically "cold" tumors require therapeutic reprogramming of the patient’s immune system to recognize and eliminate cancer cells [ 2 ]. Currently, the predominant approach used to switch on a dormant anti-tumor immune response is immunotherapy [ 3 ]. ICB, which involves inhibition of programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PDL-1), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3), promotes a robust CD8+ T cell response against cancer cells, the first step toward sustainable tumor regression [ 4 ]. However, direct inhibition of immune cells by malignant cells is not the only obstacle faced by cancer therapy. Solid tumors, especially, are poorly penetrated by lymphocytes, for multiple reasons, including absence of neoantigens, low expression of major histocompatibility complex I (MHC-I), and secretion of inhibitory cytokines such as transforming growth factor beta (TGF-β) and interleukin 10 (IL-10) [ 2 ]. Consequently, tumor relapse remains frequent, and both response and survival rates continue to be poor in a plethora of cancer entities, necessitating novel treatment approaches.

Emerging adjunct therapies are targeting the altered metabolism of cancer cells, which includes both long-known and more recently added hallmarks of cancer [ 1 , 5 ]. The most established of these metabolic characteristics is described as the Warburg effect. In order to meet the high demands in energy and biomass, concomitant with a high proliferation rate, tumor cells shift their metabolism from oxidative phosphorylation (OXPHOS) toward aerobic glycolysis. Therefore, even upon normal nutrient and oxygen availability, glucose is metabolized to pyruvate and further to lactate, allowing more rapid production of both ATP and biomass [ 6 ].

Consequently, depriving cancer cells of glucose renders them vulnerable and can therefore mitigate tumor growth [ 7 ]. This can be achieved, for example, with a high-fat low-carbohydrate ketogenic diet (KD) with adequate protein content. The low-carbohydrate content triggers the production of ketone bodies (KBs), in particular beta-hydroxybutyrate (BHB) and acetoacetate (AcAc), from fatty acids in the liver, providing an alternative energy source for extrahepatic tissues [ 8 ].

Recently, numerous preclinical studies have reported anti-tumor effects of KDs, thus supporting their use as an adjunct metabolic cancer therapy [ 9 , 10 ]. Evidence of antiproliferative effects of KDs in cancer patients, however, remains scarce, while an increase in quality of life has been reported in several clinical studies [ 9 , 11 ]. Since under a KD regimen, the energy for normal cells is supplied by KBs, KDs almost exclusively target cancer cells. A variety of cancer entities cannot use KBs because the cells lack the required enzymes and have dysfunctional mitochondria [ 12 ]. However, the cancer-starvation hypothesis has recently been questioned, since we and others have observed that blood glucose levels remain unaffected upon a KD regimen in some preclinical studies [ 9 , 13 – 16 ]. Therefore, glucose deprivation may not be the primary or sole cause of the observed anti-tumor effect of KDs. Rather other factors, for example alterations of the immune response, reduced insulin signaling, the levels of reactive oxygen species, the metabolic profile of the TME, the epigenome, and the microbiome, as well as KB-induced signaling pathways, could contribute to KD-mediated attenuation of tumor growth [ 9 , 12 , 17 ].

Recent findings also implicate immunometabolic reprogramming in the anti-tumor effect of dietary interventions [ 18 ]. However, evidence of changes in the TME induced by a KD remains scarce. Therefore, in this review, we summarize the results of existing studies of the interaction of KDs and anti-tumor immunity. Furthermore, we aim to improve understanding of this interaction and to highlight possible implications of KDs as an adjunct to ICB.

KD and the anti-tumor immune response

The mechanisms known to underlie KD treatment efficacy have recently been expanded from purely metabolic to include both epigenetic and immune-modulatory activities [ 19 ]. The effect of KDs on the anti-tumor immune response, however, remains to be fully elucidated. To date, relatively few oncological KD studies have investigated immunological aspects of the metabolic treatment [ 9 ]: seven preclinical studies have analyzed the effect of KD on immune cells in the TME of glioma [ 13 , 20 ], pancreatic cancer [ 21 ], and colon cancer [ 22 – 25 ] (Table 1 ). Notably, all of these studies also described a reduction in tumor growth and/or an increase in survival of tumor-bearing mice, pointing toward a possible connection between the observed survival benefits and immunological changes brought on by a KD. Table 1 Overview of preclinical studies reporting an effect of KD on the anti-tumor immune response Tumor type Mouse model/strain Ketogenic regimen ICB Glucose and ketone levels Effect on treatment outcome Effect on cancer cells Effect on TME Ref. Glioma Orthotopic glioblastoma C57BL/6 4:1 KD – ↑ BHB, ↔ glucose ↑ survival ↓ proliferation ↓ CD4+ T cells, ↔ CD8+ T cells, ↔ Tregs, ↓ M1 macrophages, ↑ M2 macrophages, ↑ NK cells, ↓ MDSCs [ 13 ] Orthotopic glioma C57BL/6 4:1 KD – ↑ BHB, ↓ glucose ↑ survival ↓ proliferation, ↓ expression of PDL-1, CD86 ↑ Th1 CD4+ T cells, ↔ CD8+ T cell numbe, r ↑ CD8+ T cell activity, ↔ Tregs, ↔ NK cell number, ↑ NK cell activity [ 20 ] Pancreatic Cancer s.c. pancreatic cancer C57BL/6 6:1 KD – ↑ BHB, ↓ glucose ↑ survival ↓ proliferation ↑ CD8+ T cells, ↑ CD4+ T cells, ↓ Tregs, ↓ MDSCs [ 21 ] Colon Cancer s.c. colon cancer BALB/c 4:1 KD – ↑ BHB, ↓ glucose, ↓ intratumoral lactate – ↓ proliferation ↑ M1 macrophages, ↓ M2 macrophages, ↑ NK cells, ↓ MDSCs [ 23 ] s.c. colon cancer BALB/c 4:1 KD – ↑ BHB, ↓ glucose – ↓ proliferation, ↓ expression of PDL-1, CTLA-4 ↑ Th1 CD4+ T cells, ↑ CD8+ T cell number and activity, ↔ Tregs, ↑ CCL5, CXCL9, CXCL10, CXCL11, ↑ NK cell activity [ 24 ] s.c. colorectal cancer BALB/c and C57BL/6 6:1 KD – ↑ BHB, ↓ glucose – ↓ proliferation ↑ CD4+ T cells, ↑ CD8+ T cells, ↓ Tregs, ↑ M1 macrophages, ↓ M2 macrophages, ↑ NK cells, ↓ MDSCs [ 22 ] Anti-PD-1 KD synergized with ICB, ↑ survival ↓ proliferation ↓ CXCL12 expression by CAFs, ↓ repression of immune cells s.c. colon cancer BALB/c 6:1 KD – ↓ glucose, ↓ insulin ↔ survival ↓ proliferation ↔ T cells [ 25 ] Anti-CTLA-4 KD synergized with ICB, ↑ survival ↓ proliferation, ↑ antigen presentation ↑ CD8+ T cell number and activity, ↔ CD4+ T cells, ↔ Tregs, ↑ macrophages, ↔ MDSCs Prostate Cancer s.c. prostate cancer C57BL/6 with acquired ICB resistance 3:1 cyclic KD or 1,3-butanediol suppl. anti-PD-1, anti-CTLA-4 ↑ BHB KD or BHB suppl. synergized with ICB, ↑ survival ↓ proliferation, ↑ MHC-I expression via HDACi ↑ CD8+ T cell number and activity, ↑ antigen-presenting monocytes, ↑ M1 macrophages, ↓ M2 macrophages, ↑ DCs, ↓ neutrophils, ↓ mesenchymal cells, ↑ antigen presentation and IFN-γ response genes in myeloid cells, ↑ cell-cell communications [ 55 ] Melanoma s.c. melanoma C57BL/6 4:1 KD or BHB suppl. anti-PD-1 and anti-CTLA-4 ↑ BHB KD or BHB suppl. synergized with ICB, ↑ survival ↓ proliferation – [ 33 ] Renal Cell Carcinoma orthotopic renal cancer BALB/c intermittent 4:1 KD or BHB suppl. anti-PD-1 and anti-CTLA-4 ↑ BHB KD or BHB suppl. synergized with ICB, ↑ survival ↓ proliferation – Lung Cancer orthotopic lung cancer C57BL/6 with primary ICB resistance BHB suppl. anti-PD-1 and anti-CTLA-4 ↑ BHB BHB suppl. synergized with ICB, ↑ survival ↓ proliferation – ↑: increased, ↓: decreased, ↔ : not altered, BHB: beta-hydroxybutyrate, CAFs: cancer-associated fibroblasts, CCL: C–C motif chemokine, CTLA-4: cytotoxic T lymphocyte-associated protein 4, CXCL: C-X-C motif chemokine, DCs: dendritic cells, HDACi: histone deacetylase inhibition, ICB: immune checkpoint blockade, IFN-γ: interferon gamma, KD: ketogenic diet (specified by ratio of fat [g] to the sum of proteins [g] and carbohydrates [g]), MDSCs: myeloid-derived suppressor cells, MHC-I: major histocompatibility complex 1, NK cells: natural killer cells, PD-1: programmed cell death protein 1, PDL-1: programmed cell death ligand 1, s.c.: subcutaneous, suppl.: supplementation

T cells

T cells play a pivotal role in tumor immune surveillance. They are generally perceived as highly glycolytic, especially when activated. Therefore, T cells compete with cancer cells for nutrients, particularly for glucose but also for glutamine and fatty acids, all of which are essential for both tumor cell growth and effector T cell function [ 26 , 27 ]. T lymphocytes, however, also appear to have the ability to draw energy from KBs via ketolysis [ 28 ], unlike most cancer cells. Hence, a KD could give T cells a competitive advantage over tumor cells in the context of a TME with a limited glucose supply, by providing an alternative energy source.

CD8+ T cells

In vitro studies have indeed shown that treatment of primary human peripheral blood mononuclear cells (PBMCs) with BHB augments T cell proliferation and activity [ 29 ]. Cytotoxic CD8+ T cells, especially, seem to thrive in the presence of KBs through epigenetic remodeling and even prefer BHB over glucose to fuel the tricarboxylic acid (TCA) cycle [ 28 ]. Accordingly, one of the most reported immune-modulatory effects of KDs in preclinical cancer studies is a superior CD8+ T cell-mediated anti-tumor response.

Tumor-bearing mice administered a KD have shown qualitative and/or quantitative increases in CD8+ tumor-infiltrating lymphocytes (TILs) in most preclinical studies [ 20 – 22 , 24 ]. One study of murine colon cancer indicated no significant alterations in CD8+ TILs [ 25 ]. Still, tumor infiltration by CD8+ T cells was enhanced by a KD in two other studies of murine colon cancer [ 22 , 24 ] and one of pancreatic cancer [ 21 ]. Sun et al . ascribed the observed increase in cytotoxic TILs to the upregulation of T cell-recruiting chemokines such as C–C motif chemokine 5 (CCL5), C-X-C motif chemokine 9 (CXCL9), CXCL10, and CXCL11 [ 24 ].

In studies of murine glioma, the amount of CD8+ lymphocytes detected in tumors was not different between KD- and standard diet-fed mice [ 13 , 20 ]. However, CD8+ TILs that have been detected in glioma and colon cancer showed increased activation and cytotoxicity, as indicated by elevated levels of interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and IL-2 protein [ 20 ] or RNA synthesis [ 24 ]. In glioma, the increase in T cell activation markers was concomitant with reduced levels of the exhaustion markers PD-1 and CTLA-4 involved in T cell suppression; the KD also decreased the expression of the respective ligand on the tumor cells, PDL-1, thereby hampering tumor-induced T cell inhibition [ 20 ].

Increased activity of T cells could also be explained, at least in part, by a KD-induced reduction of intratumoral lactate [ 23 , 30 ], which is known to inhibit cytotoxic T cell function [ 31 ] and impede immunotherapy efficacy [ 32 ]. However, a murine pancreatic cancer model revealed that the effects of a KD on tumor growth were less pronounced in comparison with diminished lactate dehydrogenase A, but resulted in comparable changes in immune cell infiltration [ 21 ].

In summary, KDs contribute to the alleviation of CD8+ T cell suppression and ameliorate T cell function in the TME. Of note, the survival benefit of KDs observed in murine tumor studies was diminished upon deletion of CD8+ T cells [ 20 , 33 ]. However, several studies using athymic mice, which lack functional T lymphocytes, still demonstrated an anti-tumor effect of a KD [ 9 ]. In another study directly comparing immune-compromised (athymic) and immune-competent tumor-bearing mice, KD-mediated anti-tumor activity was observed in both models. The beneficial effect was, however, notably enhanced in the presence of T cells, highlighting the impact of KD on adaptive immunity and its support of a more efficient and more durable anti-tumor response [ 34 ].

CD4+ T cells

Similarly to CD8+ T cells, CD4+ T cells have also been shown to be affected by KDs. In mouse models of glioma as well as colon and pancreatic cancer, elevated levels of CD4+ TILs were reported in KD compared to standard diet-fed mice [ 20 – 22 , 24 ], whereas the number of CD4+ TILs remained unchanged in another murine colon cancer model [ 25 ]. Interestingly, a skewing of T cell differentiation toward tumor-killing Th1 rather than immune-suppressive Th2 cells has also been observed in KD groups [ 20 , 24 ]. Therefore, a KD-boosted CD4+ T cell response could potentially contribute to the anti-tumor effects of KDs.

Regulatory CD4+ T cells (Tregs), on the other hand, seem to be scarcely affected by KDs. Tregs are recruited by the tumor to create an immune-suppressive environment and are unwanted players in the setting of cancer therapies, especially immunotherapies, as they are associated with poor outcomes and prognosis [ 35 ]. Therefore, targeting this immune-suppressive T cell subtype is an important aim in cancer immunotherapy. Considering the dependency of peripheral Tregs on fatty acid oxidation (FAO) rather than on glycolysis [ 26 ], gene expression analysis in PBMCs of healthy donors revealed that Tregs exhibit relatively high levels of OXCT1 , the gene encoding the rate-limiting enzyme of ketolysis, 3-oxoacid CoA-transferase 1 (OXCT1; also known as succinyl-CoA-3-oxaloacid CoA transferase (SCOT)) [ 36 ], indicating their ability to metabolize KBs. Indeed, in vitro experiments with human samples revealed an increase in Tregs in the presence of KBs [ 29 ]. Thus, KDs are expected to support Treg function. However, Tregs in the TME are also highly capable of using lactate as their primary energy source [ 37 ], which further enhances Treg function by upregulating TGF-β [ 38 ]. Therefore, depletion of glucose and its concomitant metabolite lactate from the TME by a KD could contribute to a decrease in the immune-suppressive and tumor-promoting activities of Tregs.

Accordingly, a KD lowered both lactate and Treg levels in pancreatic cancer-bearing mice compared to a standard diet [ 21 ]. On the other hand, tumor-infiltrating Tregs were found to be scarcely affected by a KD in two murine studies of glioma [ 13 , 20 ] and one of colon cancer [ 25 ]. The effect of a KD on Tregs in the TME therefore requires further investigation, although it may not be a primary mechanism for the anti-tumor immune response.

Memory T cell formation

A major obstacle on the path to preventing disease relapse is the lack of immunological memory formation in many tumors. Intriguingly, Yang et al. suggested that a KD can elicit a durable anti-tumor immune response, but only in the presence of T cells [ 34 ]. The ability of a KD to promote the formation of memory T cells could ensure a truly sustainable anti-tumor immune surveillance to prevent relapse in different cancer entities and therapy settings.

Indeed, the prevailing KD-associated metabolite BHB has been implicated in memory T cell formation. BHB is known to be a potent inhibitor of histone deacetylases (HDACs), which, among other histone modifications, target lysine beta-hydroxybutyrylation (Kbhb). Specifically, Kbhb of histone H3 at lysine 9 mediates the activation of a gene set involved in memory formation and maintenance. By preventing the removal of this specific modification by HDACs, BHB can induce CD8+ memory T cell formation [ 12 ]. Accordingly, Hirschberger and colleagues already showed that in vitro treatment of primary human PBMCs with BHB led to increased levels of CD4+ and CD8+ central and effector memory T cells [ 29 ]. Direct evidence of increased memory T cell formation upon a KD in tumor settings is however lacking.

Even among different cancer entities, the T cell-modulating effect of a KD has been consistently observed. There is strong evidence that a KD improves the T cell-mediated anti-tumor response by creating conditions favoring cytotoxic rather than regulatory T cells. We propose that the mechanisms underlying the effects of a KD on T cells in the TME are mediated by i) KB-sustained energy supply to T cells, which circumvents competition with cancer cells for other nutrients, ii) reduction of immune-suppressive/T cell-exhausting intratumoral lactate, and iii) a chemokine/cytokine pattern that promotes effector function, as well as the homing of cytotoxic T cells to the tumor.

Macrophages

Macrophages are also key players in the TME, and their polarization state can impact cancer progression. Macrophages can polarize either in a classically activated, pro-inflammatory, tumor-killing M1 or an alternatively activated, immune-suppressive, and tumor-promoting M2 phenotype [ 39 ]. In the TME, tumor-associated macrophages (TAMs) are present and commonly perceived as pro-tumorigenic M2-like [ 40 ]. Depending on their polarization, macrophages exhibit different metabolic properties. M1 macrophages are highly glycolytic, while M2 rely more on OXPHOS and FAO [ 41 ]. This supports the assumption that a KD can promote the polarization of macrophages in the TME toward a pro-tumorigenic M2 state, thereby contributing to an immune-suppressive environment.

Accordingly, upregulation of pro-tumorigenic M2 macrophages was observed in a KD-administered mouse model of glioblastoma. The polarization of macrophages toward a more tumor-promoting phenotype (M2) in the TME of glioblastoma was assumed to be driven by fatty acids via PPAR-γ signaling [ 13 ]. KD-fed colon cancer-bearing mice, on the other hand, presented with elevated levels of M1- and reduced M2-like macrophages [ 22 , 23 ]. However, in this latter model, application of a KD also downregulated CXCL12 secretion, which is associated with hampered infiltration by immune-suppressive macrophages [ 22 ].

Although reduction of tumor growth and an associated survival benefit of a KD were observed in all of the studies reviewed herein, the effect of a KD on macrophages seems to differ between cancer entities. This effect might depend on the metabolic profile of the specific cancer cells and of the TME, information which is largely lacking in these studies. Considering that activated M1 macrophages and TAMs are highly glycolytic, they are also fated to contest for glucose with cancer cells [ 41 ]. A KD can further decrease not only systemic but also intratumoral glucose availability [ 34 ]. Therefore, macrophages, especially classically activated ones, require alternative energy sources in the TME. Monaco et al.’s gene expression dataset revealed low levels of OXCT1 in monocytic cells [ 36 ], implying low basal KB metabolism in macrophages. In vitro experiments, however, showed that macrophages, both alternatively and classically activated, prefer AcAc over glucose to fuel the TCA cycle [ 42 ]. KBs and fatty acids could therefore fuel macrophages in the TME. BHB and fatty acids, however, are also favored by M2 polarized macrophages [ 13 , 43 ], indicating immune-suppressing effects of a KD. On the other hand, intratumoral lactate, which is a strong promotor of M2 polarization [ 44 ], was decreased by a KD [ 23 , 30 ], suggesting another mechanism for how a KD could boost the M1-mediated innate anti-tumor immune response.

Of note, TAMs display different metabolic patterns compared to M1 and M2 macrophages in the periphery, necessitating thorough investigations of their glucose, fatty acid, and KB metabolism to allow for the elucidation of KD-induced changes in TAM polarization, infiltration, and activation, and their connection to KD-mediated survival benefits in cancer models. In summary, the effect of a KD on macrophages in the TME seems less ambiguous and less substantial than that on T cells but still requires further investigation.

Natural killer (NK) cells

Apart from T cells and macrophages, little is known about the effects of KDs and KBs on other immune cells in the TME. However, some changes in the NK cell-mediated anti-tumor immune response have been reported. By recognizing tumor cells based on their lack of MHC-I expression, NK cells complement CD8+ T cells in the cytotoxic immune response to cancer cells [ 45 ].

Similar to cytotoxic T cells, NK cells exhibit glucose dependency in their activated state and require glycolysis to effectively slow tumor growth [ 46 ]. However, activated NK cells have been reported to survive under low glucose availability in the TME of multiple myeloma patients [ 47 ]. A study by Sheppard et al . revealed that fatty acids fuel NK cells, equipping them to fight malignant cells [ 48 ].

Accordingly, KDs resulted in elevated levels of NK cells in glioma- and colon cancer-bearing mice compared to standard diet-fed groups [ 13 , 22 ]. Interestingly, qualitative but not quantitative KD-induced changes in NK cells, featuring higher IFN-γ and TNF-α production by NK cells, have been observed in mouse models of glioma and colon cancer [ 20 , 24 ]. The impact of a KD on NK cells could at least partially be explained by a decrease in intratumoral lactate, alleviating the suppression of NK cell activity by lactate [ 21 , 32 ]. Furthermore, the competition of NK cells with cancer cells for glucose could explain why a KD, supplying an alternative energy source via KBs, ameliorates an NK cell-mediated anti-tumor immune response. Gene expression analysis proved OXCT1 expression in NK cells of healthy donors [ 36 ], indicating the ability of NK cells to use KBs for energy supply. However, knowledge on the capability of NK cells to metabolize KBs is lacking, requiring further investigation.

Myeloid-derived suppressor cells (MDSCs)

MDSCs complement Tregs and M2 macrophages in the immune-suppressive and tumor-promoting niche of the TME, and are similarly associated with poor clinical outcomes in cancer patients. Targeting MDSCs in cancer therapy has therefore gained importance in recent years [ 49 ].

In the TME, MDSC proliferation and function are fostered by glycolysis and FAO, respectively [ 50 ]. Considering that fatty acids have been reported to promote the immune-suppressive activity of MDSCs [ 51 ], application of a KD might even support the immune-suppressive properties of MDSCs.

Yet, murine studies of glioblastoma, colon cancer, and pancreatic cancer reported a reduction of tumor-infiltrating MDSCs in KD-fed compared to standard diet-fed mice, helping to overcome immune evasion [ 13 , 21 , 22 ]. Since lactate is known to promote the development of MDSCs [ 21 ], a KD-associated decline of intratumoral lactate could explain the observed reduction of tumor-infiltrating MDSCs. Knowledge about KB metabolism in MDSCs is scarce, making the search for mechanisms underlying the decrease of MDSCs in the TME, other than lactate-deprivation, rather difficult. Wei et al . , however, demonstrated a decrease in cancer-associated fibroblasts (CAFs) accompanying reduced infiltration by MDSCs in colon cancer-bearing mice receiving a KD [ 22 ]. Considering that CAFs are involved in the recruitment of immune-suppressive cells, including MDSCs, to the TME [ 52 ], a KD-mediated reduction of CAFs could contribute to the lower number of tumor-infiltrating MDSCs.

In conclusion, the relationship between a KD and a possible anti-tumor immune response is exceedingly complex. Deciphering this interplay could pave the way for new treatment strategies. Further research will enable better understanding of the interaction between tumor, immune system and metabolism, as well as the effect of metabolic therapies on this interplay.

KD as an adjunct metabolic therapy to support immune checkpoint blockade

The herein described studies, which strongly implicate a link between cancer immune surveillance and KD regimens, support further investigation of combined KD and ICB anticancer therapy. Although ICB substantially improves survival outcomes for various cancer entities, it still has various limitations, including metabolic barriers, which often prevent sustainable remission [ 53 ]. Metabolic barriers such as hypoxia, competition for nutrients, and high lactate levels in the TME pose obstacles to immunotherapy [ 54 ], but could potentially be targeted by a therapeutic KD regimen.

We know of four preclinical studies which have investigated the effect of a KD or BHB-supplemented standard diet as an adjunct to immunotherapy to overcome these hurdles. In prostate cancer [ 55 ], colon cancer [ 22 , 25 ], melanoma, renal cancer, and lung cancer [ 33 ], KDs as well as BHB-supplemented standard diets synergized with ICB therapy to slow tumor growth and to improve survival, even in tumors resistant to ICB monotherapy [ 33 , 55 ] (Table 1 ). The superior outcome of anti-PD-1 and anti-CTLA-4 therapy observed upon a concomitant administration of a KD was mimicked or even excelled by BHB supplementation in murine models of prostate, renal and lung cancers as well as melanoma [ 33 , 55 ].

As outlined above, KDs dampen immunosuppression and boost the anti-tumor immune response in several tumor entities. Similarly, an increase in tumor-killing M1 macrophages, as well as quantitative and qualitative enhancement of CD8+ T cells, as indicated by increased IFN-γ, granzyme B, TNF-α, and IL-2 expression, was ascribed to the addition of a KD to an anti-PD-1 and/or anti-CTLA-4 treatment in prostate and colon cancers. Concomitantly, infiltration by pro-tumorigenic immune cells such as M2 macrophages, Tregs, and MDSCs was mitigated or not affected by a KD boost [ 25 , 55 ]. Moreover, immunosuppression was further decreased by downregulation of PDL-1 on macrophages in the TME of melanoma-bearing mice and on colon cancer cells [ 25 , 33 ]. Dai et al . explained this effect as being mediated by upregulation of AMP-activated protein kinase (AMPK) upon KD administration, since AMPK can initiate the degradation of PDL-1 [ 25 ]. Generally, the communicative networks in the TME were strengthened, as antigen-presenting pathways were upregulated in immune and tumor cells with combination KD and ICB therapy [ 25 , 55 ].

Other mechanisms that may underlie the observed benefits include epigenetic alterations, i.e., BHB-mediated HDAC inhibition, since histone deacetylation poses a potential vulnerability to overcome resistance to immune therapy [ 56 ]. Of note, Murphy et al . reported that HDAC inhibition upregulated MHC-I expression on tumor cells, thereby enhancing their immunogenicity [ 55 ].

Furthermore, a KD-induced reduction of intratumoral lactate could support ICB. Lactate not only attenuates the function of cytotoxic immune cells while promoting immune-suppressive cells in the TME, it also decreases the efficacy of anti-PD-1 immunotherapy [ 57 ]. A KD could therefore alleviate these lactate-mediated barriers to ICB therapy success.

Overall, these studies evidently show that a KD can sensitize tumors, even those with initial resistance, to ICB therapy via a plethora of different mechanisms to slow tumor growth and prolong survival in murine models.

Conclusions

Until now, blocking vital metabolic pathways to target cancer cells has been perceived to be rather challenging, because metabolically similar, activated, inflammatory immune cells will often be affected as well, hampering an effective anti-tumor immune response. A KD could help to overcome this limitation, as cytotoxic immune cells could be fueled by KBs, while immune-suppressive cells and cancer cells, largely unable to metabolize BHB, will perish due to nutrient deprivation.

Accordingly, the studies we reviewed herein demonstrate that a KD remodels the TME, contributing to an eradication of cancer cells in preclinical tumor models (Fig. 1 ). Even though the most prominently reported immune-stimulatory effects of a KD are related to T cells and macrophages, effects on other immune cell populations are also suggested. It remains to be further elucidated how a KD impacts distinct subtypes of cells in the TME which until now have not been well-investigated, for example, B cells, CAFs, and dendritic cells. Moreover, further studies should aim to illuminate the relationship between metabolic and immunological changes in the TME to pinpoint KD-mediated mechanisms. Fig. 1 Proposed model of KD-induced reprogramming of an anti-tumor immune response: KD induces a decrease (↓) in glucose and lactate levels but an increase (↑) in ketone bodies, primarily beta-hydroxybutyrate (BHB). KD promotes anti-tumor immunity (positively affecting CD8+ T cells, CD4+ T cells, M1 macrophages, natural killer (NK) cells) and alleviates immune-suppression (negatively affecting regulatory T cells (Tregs), M2 macrophages, myeloid-derived suppressor cells (MDSC), tumor cells), leading to increased efficacy of immune checkpoint blockade (ICB) therapy. Note: CCL: C–C motif chemokine, CXCL: C-X-C motif chemokine, HDACi: histone deacetylase inhibition, IFN-γ: interferon gamma, MHC-I: major histocompatibility complex 1, PDL-1: programmed cell death ligand 1, TGF-β: transforming growth factor beta, TME: tumor microenvironment. (Created in BioRender. Stefan, V. (2024) BioRender.com/w68z545)

Owing to the above-described immune-modulatory activities of KDs, the dietary intervention was successful in sensitizing even resistant tumors to ICB therapy [ 33 , 55 ]. The combination of a KD with ICB elicited a superior anti-tumor immune response, mitigated tumor growth, and prolonged survival in five different murine tumor entities (Table 1 ). Intriguingly, this combinatorial treatment regimen induced long-lasting, specific immunity and prevented tumor growth upon rechallenge in a mouse model of lung cancer [ 33 ]. Exploring whether and how a KD contributes to the establishment of long-lasting anti-tumor immune memory, and potentially aids in relapse prevention, will be crucial for determining its clinical relevance.

While preclinical studies of KD-ICB combinations are scarce, there are no reports from clinical studies so far. There is, however, evidence that a similar ketosis-inducing regimen, the so-called fasting-mimicking diet, mediates superior anti-tumor immune responses and synergizes with ICB in clinical trials [ 58 – 60 ]. Recently, recruitment for one of the first studies combining KD and ICB for the treatment of renal cell carcinoma, “KETOREIN”; was initiated ( NCT05119010 ). Prospectively, in addition to ICB, CAR-T cell therapy has great potential to benefit from a KD, considering the stimulatory and the exhaustion-preventing effects of a KD on T cells.

In summary, KD has immune-modulatory effects that could boost an anti-tumor immune response, thus supporting the initiation of clinical studies combining ICB with a KD.

Abbreviations

Acetoacetate

AMP-activated protein kinase

Beta-hydroxybutyrate

Cancer-associated fibroblast

C–C motif chemokine

Cytotoxic T lymphocyte-associated protein 4

C-X-C motif chemokine

Fatty acid oxidation

Histone deacetylase

Immune checkpoint blockade

Interferon gamma

Interleukin

Lysine beta-hydroxybutyrylation

Ketone body

Ketogenic diet

Lymphocyte-activation gene 3

Myeloid-derived suppressor cell

Major histocompatibility complex 1

Natural killer cell

3-Oxoacid CoA-transferase 1

Oxidative phosphorylation

Programmed cell death protein 1

Programmed cell death ligand 1

Succinyl-CoA-3-oxaloacid CoA transferase

Tricarboxylic acid

Transforming growth factor beta

Tumor-infiltrating lymphocyte

Tumor microenvironment

Tumor necrosis factor alpha

Regulatory T cell

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author's contribution

VES drafted the manuscript, collected the related references, and prepared the table and figure. DDW participated in the discussion of the manuscript. DDW, RL, and BK critically revised the manuscript and contributed important intellectual content. All authors contributed to this manuscript. All authors read and approved the final manuscript.

Funding

Open access funding provided by Paracelsus Medical University. This work was supported by the Children's Cancer Foundation Salzburg, Austria.

Data availability

No datasets were generated or analyzed during the current study.

Declarations

Conflict of interest

RL declares relevant financial activities (travel support from Bristol-Myers Squibb, Sanofi-Aventis; research grant from Bristol-Myers Squibb (institution)). VES, DDW, and BK declare no conflicts of interest.

References

1. Hanahan D Hallmarks of cancer: new dimensions Cancer Discov 2022 12 1 31 46 35022204 10.1158/2159-8290.CD-21-1059 Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12(1):31–46 35022204 10.1158/2159-8290.CD-21-1059

2. Wang M Wang S Desai J Trapani JA Neeson PJ Therapeutic strategies to remodel immunologically cold tumors Clin Transl Immunology 2020 9 12 e1226 35136604 10.1002/cti2.1226 PMC8809427 Wang M, Wang S, Desai J, Trapani JA, Neeson PJ (2020) Therapeutic strategies to remodel immunologically cold tumors. Clin Transl Immunology 9(12):e1226 35136604 10.1002/cti2.1226 PMC8809427

3. Wang Y Zhang H Liu C Wang Z Wu W Zhang N Zhang L Hu J Luo P Zhang J Liu Z Peng Y Liu Z Tang L Cheng Q Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts J Hematol Oncol 2022 15 1 111 35978433 10.1186/s13045-022-01325-0 PMC9386972 Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, Zhang L, Hu J, Luo P, Zhang J, Liu Z, Peng Y, Liu Z, Tang L, Cheng Q (2022) Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol 15(1):111 35978433 10.1186/s13045-022-01325-0 PMC9386972

4. Seidel JA Otsuka A Kabashima K Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations Front Oncol 2018 8 86 29644214 10.3389/fonc.2018.00086 PMC5883082 Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86 29644214 10.3389/fonc.2018.00086 PMC5883082

5. Hanahan D Weinberg RA Hallmarks of cancer: the next generation Cell 2011 144 5 646 674 21376230 10.1016/j.cell.2011.02.013 Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674 21376230 10.1016/j.cell.2011.02.013

6. Warburg O On the origin of cancer cells Science 1956 123 3191 309 314 13298683 10.1126/science.123.3191.309 Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314 13298683 10.1126/science.123.3191.309

7. Mathews EH Visagie MH Meyer AA Joubert AM Mathews GE In vitro quantification: Long-term effect of glucose deprivation on various cancer cell lines Nutrition 2020 74 110748 32203880 10.1016/j.nut.2020.110748 Mathews EH, Visagie MH, Meyer AA, Joubert AM, Mathews GE (2020) In vitro quantification: Long-term effect of glucose deprivation on various cancer cell lines. Nutrition 74:110748 32203880 10.1016/j.nut.2020.110748

8. Williams MS Turos E The chemistry of the ketogenic diet: updates and opportunities in organic synthesis Int J Mol Sci 2021 22 10 5230 34063366 10.3390/ijms22105230 PMC8157195 Williams MS, Turos E (2021) The chemistry of the ketogenic diet: updates and opportunities in organic synthesis. Int J Mol Sci 22(10):5230 34063366 10.3390/ijms22105230 PMC8157195

9. Weber DD Aminzadeh-Gohari S Tulipan J Catalano L Feichtinger RG Kofler B Ketogenic diet in the treatment of cancer - Where do we stand? Mol Metab 2020 33 102 121 31399389 10.1016/j.molmet.2019.06.026 PMC7056920 Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B (2020) Ketogenic diet in the treatment of cancer - Where do we stand? Mol Metab 33:102–121 31399389 10.1016/j.molmet.2019.06.026 PMC7056920

10. Klement RJ Anti-tumor effects of ketogenic diets and their synergism with other treatments in mice: Bayesian evidence synthesis of 1755 individual mouse survival data Biomed J 2024 47 1 100609 37245566 10.1016/j.bj.2023.100609 PMC10900256 Klement RJ (2024) Anti-tumor effects of ketogenic diets and their synergism with other treatments in mice: Bayesian evidence synthesis of 1755 individual mouse survival data. Biomed J 47(1):100609 37245566 10.1016/j.bj.2023.100609 PMC10900256

11. Seyfried TN Mukherjee P Iyikesici MS Slocum A Kalamian M Spinosa JP Chinopoulos C Consideration of ketogenic metabolic therapy as a complementary or alternative approach for managing breast cancer Front Nutr 2020 7 21 32219096 10.3389/fnut.2020.00021 PMC7078107 Seyfried TN, Mukherjee P, Iyikesici MS, Slocum A, Kalamian M, Spinosa JP, Chinopoulos C (2020) Consideration of ketogenic metabolic therapy as a complementary or alternative approach for managing breast cancer. Front Nutr 7:21 32219096 10.3389/fnut.2020.00021 PMC7078107

12. Hwang CY Choe W Yoon K-S Ha J Kim SS Yeo E-J Kang I Molecular mechanisms for ketone body metabolism, signaling functions, and therapeutic potential in cancer Nutrients 2022 14 22 4932 36432618 10.3390/nu14224932 PMC9694619 Hwang CY, Choe W, Yoon K-S, Ha J, Kim SS, Yeo E-J, Kang I (2022) Molecular mechanisms for ketone body metabolism, signaling functions, and therapeutic potential in cancer. Nutrients 14(22):4932 36432618 10.3390/nu14224932 PMC9694619

13. Kesarwani P Kant S Zhao Y Miller CR Chinnaiyan P The influence of the ketogenic diet on the immune tolerant microenvironment in glioblastoma Cancers 2022 14 22 5550 36428642 10.3390/cancers14225550 PMC9688691 Kesarwani P, Kant S, Zhao Y, Miller CR, Chinnaiyan P (2022) The influence of the ketogenic diet on the immune tolerant microenvironment in glioblastoma. Cancers 14(22):5550 36428642 10.3390/cancers14225550 PMC9688691

14. Licha D Vidali S Aminzadeh-Gohari S Alka O Breitkreuz L Kohlbacher O Reischl RJ Feichtinger RG Kofler B Huber CG Untargeted metabolomics reveals molecular effects of ketogenic diet on healthy and tumor xenograft mouse models Int J Mol Sci 2019 20 16 3873 31398922 10.3390/ijms20163873 PMC6719192 Licha D, Vidali S, Aminzadeh-Gohari S, Alka O, Breitkreuz L, Kohlbacher O, Reischl RJ, Feichtinger RG, Kofler B, Huber CG (2019) Untargeted metabolomics reveals molecular effects of ketogenic diet on healthy and tumor xenograft mouse models. Int J Mol Sci 20(16):3873 31398922 10.3390/ijms20163873 PMC6719192

15. Morscher RJ Aminzadeh-Gohari S Feichtinger RG Mayr JA Lang R Neureiter D Sperl W Kofler B Inhibition of neuroblastoma tumor growth by ketogenic diet and/or calorie restriction in a CD1-Nu mouse model PLoS ONE 2015 10 6 e0129802 26053068 10.1371/journal.pone.0129802 PMC4459995 Morscher RJ, Aminzadeh-Gohari S, Feichtinger RG, Mayr JA, Lang R, Neureiter D, Sperl W, Kofler B (2015) Inhibition of neuroblastoma tumor growth by ketogenic diet and/or calorie restriction in a CD1-Nu mouse model. PLoS ONE 10(6):e0129802 26053068 10.1371/journal.pone.0129802 PMC4459995

16. Morscher RJ Aminzadeh-Gohari S Hauser-Kronberger C Feichtinger RG Sperl W Kofler B Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model Oncotarget 2016 7 13 17060 17073 26959744 10.18632/oncotarget.7929 PMC4941371 Morscher RJ, Aminzadeh-Gohari S, Hauser-Kronberger C, Feichtinger RG, Sperl W, Kofler B (2016) Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model. Oncotarget 7(13):17060–17073 26959744 10.18632/oncotarget.7929 PMC4941371

17. Boison D New insights into the mechanisms of the ketogenic diet Curr Opin Neurol 2017 30 2 187 192 28141738 10.1097/WCO.0000000000000432 PMC5409832 Boison D (2017) New insights into the mechanisms of the ketogenic diet. Curr Opin Neurol 30(2):187–192 28141738 10.1097/WCO.0000000000000432 PMC5409832

18. Soldati L Di Renzo L Jirillo E Ascierto PA Marincola FM De Lorenzo A The influence of diet on anti-cancer immune responsiveness J Transl Med 2018 16 1 75 29558948 10.1186/s12967-018-1448-0 PMC5859494 Soldati L, Di Renzo L, Jirillo E, Ascierto PA, Marincola FM, De Lorenzo A (2018) The influence of diet on anti-cancer immune responsiveness. J Transl Med 16(1):75 29558948 10.1186/s12967-018-1448-0 PMC5859494

19. Srivastava S Pawar VA Tyagi A Sharma KP Kumar V Shukla SK Immune modulatory effects of ketogenic diet in different disease conditions Immuno 2023 3 1 1 15 Srivastava S, Pawar VA, Tyagi A, Sharma KP, Kumar V, Shukla SK (2023) Immune modulatory effects of ketogenic diet in different disease conditions. Immuno 3(1):1–15

20. Lussier DM Woolf EC Johnson JL Brooks KS Blattman JN Scheck AC Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet BMC Cancer 2016 16 310 27178315 10.1186/s12885-016-2337-7 PMC4866042 Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC (2016) Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet. BMC Cancer 16:310 27178315 10.1186/s12885-016-2337-7 PMC4866042

21. Husain Z Huang Y Seth P Sukhatme VP Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells J Immunol 2013 191 3 1486 1495 23817426 10.4049/jimmunol.1202702 Husain Z, Huang Y, Seth P, Sukhatme VP (2013) Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol 191(3):1486–1495 23817426 10.4049/jimmunol.1202702

22. Wei R Zhou Y Li C Rychahou P Zhang S Titlow WB Bauman G Wu Y Liu J Wang C Weiss HL Evers BM Wang Q Ketogenesis attenuates KLF5-dependent production of CXCL12 to overcome the immunosuppressive Tumor microenvironment in colorectal cancer Cancer Res 2022 82 8 1575 1588 35247887 10.1158/0008-5472.CAN-21-2778 PMC9018557 Wei R, Zhou Y, Li C, Rychahou P, Zhang S, Titlow WB, Bauman G, Wu Y, Liu J, Wang C, Weiss HL, Evers BM, Wang Q (2022) Ketogenesis attenuates KLF5-dependent production of CXCL12 to overcome the immunosuppressive Tumor microenvironment in colorectal cancer. Cancer Res 82(8):1575–1588 35247887 10.1158/0008-5472.CAN-21-2778 PMC9018557

23. Zhang N Liu C Jin L Zhang R Wang T Wang Q Chen J Yang F Siebert HC Zheng X Ketogenic diet elicits antitumor properties through inducing oxidative stress, inhibiting MMP-9 expression, and rebalancing M1/M2 Tumor-associated macrophage phenotype in a mouse model of colon cancer J Agric Food Chem 2020 68 40 11182 11196 32786841 10.1021/acs.jafc.0c04041 Zhang N, Liu C, Jin L, Zhang R, Wang T, Wang Q, Chen J, Yang F, Siebert HC, Zheng X (2020) Ketogenic diet elicits antitumor properties through inducing oxidative stress, inhibiting MMP-9 expression, and rebalancing M1/M2 Tumor-associated macrophage phenotype in a mouse model of colon cancer. J Agric Food Chem 68(40):11182–11196 32786841 10.1021/acs.jafc.0c04041

24. Sun W Yang J Liu B Liu Q Wang T Wang Q Liu M Li L Wang Z Li S Siebert H-C Zhang N Ketogenic diet inhibits Tumor growth by enhancing immune response, attenuating immunosuppression, inhibiting angiogenesis and EMT in CT26 colon Tumor allografts mouse model J Funct Foods 2022 92 105067 Sun W, Yang J, Liu B, Liu Q, Wang T, Wang Q, Liu M, Li L, Wang Z, Li S, Siebert H-C, Zhang N (2022) Ketogenic diet inhibits Tumor growth by enhancing immune response, attenuating immunosuppression, inhibiting angiogenesis and EMT in CT26 colon Tumor allografts mouse model. J Funct Foods 92:105067

25. Dai X Bu X Gao Y Guo J Hu J Jiang C Zhang Z Xu K Duan J He S Zhang J Wan L Liu T Zhou X Hung MC Freeman GJ Wei W Energy status dictates PD-L1 protein abundance and anti-Tumor immunity to enable checkpoint blockade Mol Cell 2021 81 11 2317 2331.e2316 33909988 10.1016/j.molcel.2021.03.037 PMC8178223 Dai X, Bu X, Gao Y, Guo J, Hu J, Jiang C, Zhang Z, Xu K, Duan J, He S, Zhang J, Wan L, Liu T, Zhou X, Hung MC, Freeman GJ, Wei W (2021) Energy status dictates PD-L1 protein abundance and anti-Tumor immunity to enable checkpoint blockade. Mol Cell 81(11):2317-2331.e2316 33909988 10.1016/j.molcel.2021.03.037 PMC8178223

26. Traba J Sack MN Waldmann TA Anton OM Immunometabolism at the nexus of cancer therapeutic efficacy and resistance Front Immunol 2021 12 657293 34079545 10.3389/fimmu.2021.657293 PMC8166297 Traba J, Sack MN, Waldmann TA, Anton OM (2021) Immunometabolism at the nexus of cancer therapeutic efficacy and resistance. Front Immunol 12:657293 34079545 10.3389/fimmu.2021.657293 PMC8166297

27. Cuyàs E Verdura S Martin-Castillo B Alarcón T Lupu R Bosch-Barrera J Menendez JA Tumor cell-intrinsic immunometabolism and precision nutrition in cancer immunotherapy Cancers 2020 12 7 1757 32630618 10.3390/cancers12071757 PMC7409312 Cuyàs E, Verdura S, Martin-Castillo B, Alarcón T, Lupu R, Bosch-Barrera J, Menendez JA (2020) Tumor cell-intrinsic immunometabolism and precision nutrition in cancer immunotherapy. Cancers 12(7):1757 32630618 10.3390/cancers12071757 PMC7409312

28. Luda KM Longo J Kitchen-Goosen SM Duimstra LR Ma EH Watson MJ Oswald BM Fu Z Madaj Z Kupai A Dickson BM DeCamp LM Dahabieh MS Compton SE Teis R Kaymak I Lau KH Kelly DP Puchalska P Williams KS Krawczyk CM Lévesque D Boisvert FM Sheldon RD Rothbart SB Crawford PA Jones RG Ketolysis drives CD8(+) T cell effector function through effects on histone acetylation Immunity 2023 56 9 2021 2035.e2028 37516105 10.1016/j.immuni.2023.07.002 PMC10528215 Luda KM, Longo J, Kitchen-Goosen SM, Duimstra LR, Ma EH, Watson MJ, Oswald BM, Fu Z, Madaj Z, Kupai A, Dickson BM, DeCamp LM, Dahabieh MS, Compton SE, Teis R, Kaymak I, Lau KH, Kelly DP, Puchalska P, Williams KS, Krawczyk CM, Lévesque D, Boisvert FM, Sheldon RD, Rothbart SB, Crawford PA, Jones RG (2023) Ketolysis drives CD8(+) T cell effector function through effects on histone acetylation. Immunity 56(9):2021-2035.e2028 37516105 10.1016/j.immuni.2023.07.002 PMC10528215

29. Hirschberger S Strauß G Effinger D Marstaller X Ferstl A Müller MB Wu T Hübner M Rahmel T Mascolo H Exner N Heß J Kreth FW Unger K Kreth S Very-low-carbohydrate diet enhances human T-cell immunity through immunometabolic reprogramming EMBO Mol Med 2021 13 8 e14323 34151532 10.15252/emmm.202114323 PMC8350890 Hirschberger S, Strauß G, Effinger D, Marstaller X, Ferstl A, Müller MB, Wu T, Hübner M, Rahmel T, Mascolo H, Exner N, Heß J, Kreth FW, Unger K, Kreth S (2021) Very-low-carbohydrate diet enhances human T-cell immunity through immunometabolic reprogramming. EMBO Mol Med 13(8):e14323 34151532 10.15252/emmm.202114323 PMC8350890

30. Schroeder U Himpe B Pries R Vonthein R Nitsch S Wollenberg B Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer Nutr Cancer 2013 65 6 843 849 23909728 10.1080/01635581.2013.804579 Schroeder U, Himpe B, Pries R, Vonthein R, Nitsch S, Wollenberg B (2013) Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. Nutr Cancer 65(6):843–849 23909728 10.1080/01635581.2013.804579

31. Fischer K Hoffmann P Voelkl S Meidenbauer N Ammer J Edinger M Gottfried E Schwarz S Rothe G Hoves S Renner K Timischl B Mackensen A Kunz-Schughart L Andreesen R Krause SW Kreutz M Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood 2007 109 9 3812 3819 17255361 10.1182/blood-2006-07-035972 Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, Kreutz M (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109(9):3812–3819 17255361 10.1182/blood-2006-07-035972

32. Feichtinger RG Lang R Targeting L-lactate metabolism to overcome resistance to immune therapy of melanoma and other Tumor entities J Oncol 2019 2019 2084195 31781212 10.1155/2019/2084195 PMC6875281 Feichtinger RG, Lang R (2019) Targeting L-lactate metabolism to overcome resistance to immune therapy of melanoma and other Tumor entities. J Oncol 2019:2084195 31781212 10.1155/2019/2084195 PMC6875281

33. Ferrere G Tidjani Alou M Liu P Goubet AG Fidelle M Kepp O Durand S Iebba V Fluckiger A Daillère R Thelemaque C Grajeda-Iglesias C Alves Costa Silva C Aprahamian F Lefevre D Zhao L Ryffel B Colomba E Arnedos M Drubay D Rauber C Raoult D Asnicar F Spector T Segata N Derosa L Kroemer G Zitvogel L Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade JCI Insight 2021 6 2 e145207 33320838 10.1172/jci.insight.145207 PMC7934884 Ferrere G, Tidjani Alou M, Liu P, Goubet AG, Fidelle M, Kepp O, Durand S, Iebba V, Fluckiger A, Daillère R, Thelemaque C, Grajeda-Iglesias C, Alves Costa Silva C, Aprahamian F, Lefevre D, Zhao L, Ryffel B, Colomba E, Arnedos M, Drubay D, Rauber C, Raoult D, Asnicar F, Spector T, Segata N, Derosa L, Kroemer G, Zitvogel L (2021) Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight 6(2):e145207 33320838 10.1172/jci.insight.145207 PMC7934884

34. Yang L TeSlaa T Ng S Nofal M Wang L Lan T Zeng X Cowan A McBride M Lu W Davidson S Liang G Oh TG Downes M Evans R Von Hoff D Guo JY Han H Rabinowitz JD Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth Med 2022 3 2 119 136 35425930 10.1016/j.medj.2021.12.008 PMC9004683 Yang L, TeSlaa T, Ng S, Nofal M, Wang L, Lan T, Zeng X, Cowan A, McBride M, Lu W, Davidson S, Liang G, Oh TG, Downes M, Evans R, Von Hoff D, Guo JY, Han H, Rabinowitz JD (2022) Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth. Med 3(2):119–136 35425930 10.1016/j.medj.2021.12.008 PMC9004683

35. Iglesias-Escudero M Arias-González N Martínez-Cáceres E Regulatory cells and the effect of cancer immunotherapy Mol Cancer 2023 22 1 26 36739406 10.1186/s12943-023-01714-0 PMC9898962 Iglesias-Escudero M, Arias-González N, Martínez-Cáceres E (2023) Regulatory cells and the effect of cancer immunotherapy. Mol Cancer 22(1):26 36739406 10.1186/s12943-023-01714-0 PMC9898962

36. Monaco G Lee B Xu W Mustafah S Hwang YY Carré C Burdin N Visan L Ceccarelli M Poidinger M Zippelius A Pedro de Magalhães J Larbi A RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types Cell Rep 2019 26 6 1627 1640.e1627 30726743 10.1016/j.celrep.2019.01.041 PMC6367568 Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carré C, Burdin N, Visan L, Ceccarelli M, Poidinger M, Zippelius A, Pedro de Magalhães J, Larbi A (2019) RNA-Seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cell Rep 26(6):1627-1640.e1627 30726743 10.1016/j.celrep.2019.01.041 PMC6367568

37. Watson MJ Vignali PDA Mullett SJ Overacre-Delgoffe AE Peralta RM Grebinoski S Menk AV Rittenhouse NL DePeaux K Whetstone RD Vignali DAA Hand TW Poholek AC Morrison BM Rothstein JD Wendell SG Delgoffe GM Metabolic support of tumour-infiltrating regulatory T cells by lactic acid Nature 2021 591 7851 645 651 33589820 10.1038/s41586-020-03045-2 PMC7990682 Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, Vignali DAA, Hand TW, Poholek AC, Morrison BM, Rothstein JD, Wendell SG, Delgoffe GM (2021) Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591(7851):645–651 33589820 10.1038/s41586-020-03045-2 PMC7990682

38. Gu J Zhou J Chen Q Xu X Gao J Li X Shao Q Zhou B Zhou H Wei S Wang Q Liang Y Lu L Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells Cell Rep 2022 39 12 110986 35732125 10.1016/j.celrep.2022.110986 Gu J, Zhou J, Chen Q, Xu X, Gao J, Li X, Shao Q, Zhou B, Zhou H, Wei S, Wang Q, Liang Y, Lu L (2022) Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. Cell Rep 39(12):110986 35732125 10.1016/j.celrep.2022.110986

39. Yunna C Mengru H Lei W Weidong C Macrophage M1/M2 polarization Eur J Pharmacol 2020 877 173090 32234529 10.1016/j.ejphar.2020.173090 Yunna C, Mengru H, Lei W, Weidong C (2020) Macrophage M1/M2 polarization. Eur J Pharmacol 877:173090 32234529 10.1016/j.ejphar.2020.173090

40. Chen Y Song Y Du W Gong L Chang H Zou Z Tumor-associated macrophages: an accomplice in solid tumor progression J Biomed Sci 2019 26 1 78 31629410 10.1186/s12929-019-0568-z PMC6800990 Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z (2019) Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci 26(1):78 31629410 10.1186/s12929-019-0568-z PMC6800990

41. Xiao L Wang Q Peng H Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy Front Immunol 2023 14 1157291 37426676 10.3389/fimmu.2023.1157291 PMC10325569 Xiao L, Wang Q, Peng H (2023) Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy. Front Immunol 14:1157291 37426676 10.3389/fimmu.2023.1157291 PMC10325569

42. Puchalska P Martin SE Huang X Lengfeld JE Daniel B Graham MJ Han X Nagy L Patti GJ Crawford PA Hepatocyte-macrophage acetoacetate shuttle protects against tissue fibrosis Cell Metab 2019 29 2 383 398.e387 30449686 10.1016/j.cmet.2018.10.015 PMC6559243 Puchalska P, Martin SE, Huang X, Lengfeld JE, Daniel B, Graham MJ, Han X, Nagy L, Patti GJ, Crawford PA (2019) Hepatocyte-macrophage acetoacetate shuttle protects against tissue fibrosis. Cell Metab 29(2):383-398.e387 30449686 10.1016/j.cmet.2018.10.015 PMC6559243

43. Huang C Wang J Liu H Huang R Yan X Song M Tan G Zhi F Ketone body β-hydroxybutyrate ameliorates colitis by promoting M2 macrophage polarization through the STAT6-dependent signaling pathway BMC Med 2022 20 1 148 35422042 10.1186/s12916-022-02352-x PMC9011974 Huang C, Wang J, Liu H, Huang R, Yan X, Song M, Tan G, Zhi F (2022) Ketone body β-hydroxybutyrate ameliorates colitis by promoting M2 macrophage polarization through the STAT6-dependent signaling pathway. BMC Med 20(1):148 35422042 10.1186/s12916-022-02352-x PMC9011974

44. Mu X Shi W Xu Y Xu C Zhao T Geng B Yang J Pan J Hu S Zhang C Zhang J Wang C Shen J Che Y Liu Z Lv Y Wen H You Q Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer Cell Cycle 2018 17 4 428 438 29468929 10.1080/15384101.2018.1444305 PMC5927648 Mu X, Shi W, Xu Y, Xu C, Zhao T, Geng B, Yang J, Pan J, Hu S, Zhang C, Zhang J, Wang C, Shen J, Che Y, Liu Z, Lv Y, Wen H, You Q (2018) Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle 17(4):428–438 29468929 10.1080/15384101.2018.1444305 PMC5927648

45. Vojdani A Koksoy S Vojdani E Engelman M Benzvi C Lerner A Natural killer cells and cytotoxic T cells: complementary partners against microorganisms and cancer Microorganisms 2024 12 1 230 38276215 10.3390/microorganisms12010230 PMC10818828 Vojdani A, Koksoy S, Vojdani E, Engelman M, Benzvi C, Lerner A (2024) Natural killer cells and cytotoxic T cells: complementary partners against microorganisms and cancer. Microorganisms 12(1):230 38276215 10.3390/microorganisms12010230 PMC10818828

46. Isaacson B Mandelboim O Sweet killers: NK cells need glycolysis to kill Tumors Cell Metab 2018 28 2 183 184 30089237 10.1016/j.cmet.2018.07.008 Isaacson B, Mandelboim O (2018) Sweet killers: NK cells need glycolysis to kill Tumors. Cell Metab 28(2):183–184 30089237 10.1016/j.cmet.2018.07.008

47. Ehlers FAI Mahaweni NM Olieslagers TI Bos GMJ Wieten L Activated natural killer cells withstand the relatively low glucose concentrations found in the bone marrow of multiple myeloma patients Front Oncol 2021 11 622896 34094908 10.3389/fonc.2021.622896 PMC8174784 Ehlers FAI, Mahaweni NM, Olieslagers TI, Bos GMJ, Wieten L (2021) Activated natural killer cells withstand the relatively low glucose concentrations found in the bone marrow of multiple myeloma patients. Front Oncol. 11:622896 34094908 10.3389/fonc.2021.622896 PMC8174784

48. Sheppard S Srpan K Lin W Lee M Delconte RB Owyong M Carmeliet P Davis DM Xavier JB Hsu KC Sun JC Fatty acid oxidation fuels natural killer cell responses against infection and cancer Proc Natl Acad Sci U S A 2024 121 11 e2319254121 38442180 10.1073/pnas.2319254121 PMC10945797 Sheppard S, Srpan K, Lin W, Lee M, Delconte RB, Owyong M, Carmeliet P, Davis DM, Xavier JB, Hsu KC, Sun JC (2024) Fatty acid oxidation fuels natural killer cell responses against infection and cancer. Proc Natl Acad Sci U S A 121(11):e2319254121 38442180 10.1073/pnas.2319254121 PMC10945797

49. Lu J Luo Y Rao D Wang T Lei Z Chen X Zhang B Li Y Liu B Xia L Huang W Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion Exp Hematol Oncol 2024 13 1 39 38609997 10.1186/s40164-024-00505-7 PMC11010322 Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X, Zhang B, Li Y, Liu B, Xia L, Huang W (2024) Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol 13(1):39 38609997 10.1186/s40164-024-00505-7 PMC11010322

50. Li J Bolyard C Xin G Li Z Targeting metabolic pathways of myeloid cells improves cancer immunotherapy Front Cell Dev Biol 2021 10.3389/fcell.2021.747863 34988072 PMC8721007 Li J, Bolyard C, Xin G, Li Z (2021) Targeting metabolic pathways of myeloid cells improves cancer immunotherapy. Front Cell Dev Biol. 9:747863 34988072 10.3389/fcell.2021.747863 PMC8721007

51. Yan D Adeshakin AO Xu M Afolabi LO Zhang G Chen YH Wan X Lipid metabolic pathways confer the immunosuppressive function of myeloid-derived suppressor cells in Tumor Front Immunol 2019 10 1399 31275326 10.3389/fimmu.2019.01399 PMC6593140 Yan D, Adeshakin AO, Xu M, Afolabi LO, Zhang G, Chen YH, Wan X (2019) Lipid metabolic pathways confer the immunosuppressive function of myeloid-derived suppressor cells in Tumor. Front Immunol 10:1399 31275326 10.3389/fimmu.2019.01399 PMC6593140

52. Arpinati L Scherz-Shouval R From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts Trends Cancer 2023 9 5 421 443 36870916 10.1016/j.trecan.2023.01.007 Arpinati L, Scherz-Shouval R (2023) From gatekeepers to providers: regulation of immune functions by cancer-associated fibroblasts. Trends Cancer 9(5):421–443 36870916 10.1016/j.trecan.2023.01.007

53. Bagchi S Yuan R Engleman EG Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance Annu Rev Pathol 2021 16 223 249 33197221 10.1146/annurev-pathol-042020-042741 Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223–249 33197221 10.1146/annurev-pathol-042020-042741

54. DePeaux K Delgoffe GM Metabolic barriers to cancer immunotherapy Nat Rev Immunol 2021 21 12 785 797 33927375 10.1038/s41577-021-00541-y PMC8553800 DePeaux K, Delgoffe GM (2021) Metabolic barriers to cancer immunotherapy. Nat Rev Immunol 21(12):785–797 33927375 10.1038/s41577-021-00541-y PMC8553800

55. Murphy S Rahmy S Gan D Liu G Zhu Y Manyak M Duong L He J Schofield JH Schafer ZT Li J Lu X Lu X Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy Cancer Res 2024 84 10 1597 1612 38588411 10.1158/0008-5472.CAN-23-2742 PMC11096030 Murphy S, Rahmy S, Gan D, Liu G, Zhu Y, Manyak M, Duong L, He J, Schofield JH, Schafer ZT, Li J, Lu X, Lu X (2024) Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy. Cancer Res 84(10):1597–1612 38588411 10.1158/0008-5472.CAN-23-2742 PMC11096030

56. Weintraub K Take two: combining immunotherapy with epigenetic drugs to tackle cancer Nat Med 2016 22 1 8 10 26735398 10.1038/nm0116-8 Weintraub K (2016) Take two: combining immunotherapy with epigenetic drugs to tackle cancer. Nat Med 22(1):8–10 26735398 10.1038/nm0116-8

57. Chen S Zhou X Yang X Li W Li S Hu Z Ling C Shi R Liu J Chen G Song N Jiang X Sui X Gao Y Dual blockade of lactate/GPR81 and PD-1/PD-L1 pathways enhances the anti-Tumor effects of metformin Biomolecules 2021 11 9 1373 34572586 10.3390/biom11091373 PMC8466555 Chen S, Zhou X, Yang X, Li W, Li S, Hu Z, Ling C, Shi R, Liu J, Chen G, Song N, Jiang X, Sui X, Gao Y (2021) Dual blockade of lactate/GPR81 and PD-1/PD-L1 pathways enhances the anti-Tumor effects of metformin. Biomolecules 11(9):1373 34572586 10.3390/biom11091373 PMC8466555

58. Vernieri C Fucà G Ligorio F Huber V Vingiani A Iannelli F Raimondi A Rinchai D Frigè G Belfiore A Lalli L Chiodoni C Cancila V Zanardi F Ajazi A Cortellino S Vallacchi V Squarcina P Cova A Pesce S Frati P Mall R Corsetto PA Rizzo AM Ferraris C Folli S Garassino MC Capri G Bianchi G Colombo MP Minucci S Foiani M Longo VD Apolone G Torri V Pruneri G Bedognetti D Rivoltini L de Braud F Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in patients with cancer Cancer Discov 2022 12 1 90 107 34789537 10.1158/2159-8290.CD-21-0030 PMC9762338 Vernieri C, Fucà G, Ligorio F, Huber V, Vingiani A, Iannelli F, Raimondi A, Rinchai D, Frigè G, Belfiore A, Lalli L, Chiodoni C, Cancila V, Zanardi F, Ajazi A, Cortellino S, Vallacchi V, Squarcina P, Cova A, Pesce S, Frati P, Mall R, Corsetto PA, Rizzo AM, Ferraris C, Folli S, Garassino MC, Capri G, Bianchi G, Colombo MP, Minucci S, Foiani M, Longo VD, Apolone G, Torri V, Pruneri G, Bedognetti D, Rivoltini L, de Braud F (2022) Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in patients with cancer. Cancer Discov 12(1):90–107 34789537 10.1158/2159-8290.CD-21-0030 PMC9762338

59. Ligorio F Fucà G Provenzano L Lobefaro R Zanenga L Vingiani A Belfiore A Lorenzoni A Alessi A Pruneri G de Braud F Vernieri C Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: a sub-analysis of the NCT03340935 trial Eur J Cancer 2022 172 300 310 35810555 10.1016/j.ejca.2022.05.046 Ligorio F, Fucà G, Provenzano L, Lobefaro R, Zanenga L, Vingiani A, Belfiore A, Lorenzoni A, Alessi A, Pruneri G, de Braud F, Vernieri C (2022) Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: a sub-analysis of the NCT03340935 trial. Eur J Cancer 172:300–310 35810555 10.1016/j.ejca.2022.05.046

60. Blaževitš O Di Tano M Longo VD Fasting and fasting mimicking diets in cancer prevention and therapy Trends Cancer 2023 9 3 212 222 36646607 10.1016/j.trecan.2022.12.006 Blaževitš O, Di Tano M, Longo VD (2023) Fasting and fasting mimicking diets in cancer prevention and therapy. Trends Cancer 9(3):212–222 36646607 10.1016/j.trecan.2022.12.006